UniQure pauses dosing in Fabry disease trial amid safety concerns
UniQure has ceased dosing in two cohorts in a Phase I/IIa trial of its adeno-associated viral (AAV) gene therapy, AMT-191,…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
£1bn London Cancer Hub extension gets go-ahead amid UK life sciences push
The London Cancer Hub, a key centre for the UK’s oncology research output, is undergoing a major expansion to increase…
-
NMD Pharma to progress CMT pill despite primary endpoint miss
NMD Pharma is “accelerating development” of its lead rare disease candidate, ignaseclant, in Charcot-Marie-Tooth (CMT), despite the drug failing to…
-
Artivion’s aortic stents boost post-surgical outcomes in interventional studies
Artivion has debuted long-term clinical data on two of its cardiac stent products, revealing each’s solution’s potential to offer extended…
-
Biorce secures $52.5m in Series A to expand AI clinical trial tech
Spanish healthtech company Biorce has secured $52.5m through a Series A funding round to support the global rollout of its…
-
CalciMedica’s stock drops 75% on acute kidney injury trial termination
CalciMedica has terminated a Phase II study on its lead asset, Auxora (zegocractin), in acute kidney injury (AKI) with associated…
-
Sarepta eyes Elevidys sales comeback with positive Phase III data
Following a tough 2025 for Sarepta, the biotech has posted positive, long-term Phase III data on its Duchenne muscular dystrophy…
-
Bausch Health’s new formulation of Xifaxan fails pair of Phase III trials
A new formulation of Bausch Health’s Xifaxan (rifaximin) has failed to demonstrate efficacy in two Phase III studies in hepatic…
-
ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study
ImmunityBio’s immunotherapy combination regimen has demonstrated its early potential during a mid-stage trial in patients with glioblastoma and severe lymphopenia.…
-
Sanofi’s Dupixent successor heads to regulators after Phase III success
Sanofi has debuted the long-awaited results from two Phase III studies of its potential Dupixent (dupilumab) successor, amlitelimab, in atopic…